.Pharmacolibrary.Drugs.N_NervousSystem.N04B_DopaminergicAgents.N04BA02_LevodopaAndDecarboxylaseInhibito.LevodopaAndDecarboxylaseInhibito .Pharmacolibrary.Drugs.N_NervousSystem.N04B_DopaminergicAgents.N04BA02_LevodopaAndDecarboxylaseInhibito.LevodopaAndDecarboxylaseInhibito| name: | LevodopaAndDecarboxylaseInhibitor |
| ATC code: | N04BA02 | route: | oral |
| n-compartments | 2 |
Levodopa and decarboxylase inhibitor is a combination drug used in the management of Parkinson's disease. Levodopa is a precursor of dopamine, which is deficient in patients with Parkinson's disease, and the decarboxylase inhibitor (usually carbidopa or benserazide) prevents the peripheral breakdown of levodopa, increasing its availability to the brain. This therapy is widely used and approved in clinical practice.
Pharmacokinetic parameters reported for adult patients with Parkinson's disease receiving oral levodopa/benserazide (100 mg/25 mg) with blood sampling in a fasted state.
Rouru, J, et al., & Scheinin, M (1999). Pharmacokinetics of oral entacapone after frequent multiple dosing and effects on levodopa disposition. European journal of clinical pharmacology 55(6) 461–467. DOI:10.1007/s002280050657 PUBMED:https://pubmed.ncbi.nlm.nih.gov/10492060
Bianchine, JR, & Shaw, GM (1976). Clinical pharmacokinetics of levodopa in parkinson's disease. Clinical pharmacokinetics 1(5) 313–338. DOI:10.2165/00003088-197601050-00001 PUBMED:https://pubmed.ncbi.nlm.nih.gov/797502
Scott, LJ (2016). Opicapone: A Review in Parkinson's Disease. Drugs 76(13) 1293–1300. DOI:10.1007/s40265-016-0623-y PUBMED:https://pubmed.ncbi.nlm.nih.gov/27498199